Dallas, TX -- (SBWIRE) -- 06/02/2015 -- The report "Mild Psoriasis – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Mild Psoriasis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on H1 2015 pipeline review of Mild Psoriasis with 23 market data tables and 14 figures, spread across 48 pages is available at http://www.rnrmarketresearch.com/mild-psoriasis-pipeline-review-h1-2015-market-report.html

Companies discussed in this Mild Psoriasis – Pipeline Review, H1 2015 report include Almirall, S.A., Avexxin AS, Convoy Therapeutics, Inc., Delenex Therapeutics AG, GlycoMar Limited, OPKO Health, Inc., Soligenix, Inc., UCB S.A.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are AKP-11, AVX-001, cyclosporine, DLX-105, DLX-3003, GLY-2028, lunacalcipol, SGX-301, tazarotene, UCB-5857.

Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=386036
(This is a premium report priced at US$2000 for a single user License.)

List of Tables
Number of Products under Development for Mild Psoriasis, H1 2015 7
Number of Products under Development for Mild Psoriasis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Comparative Analysis by Early Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Mild Psoriasis - Pipeline by Almirall, S.A., H1 2015 13
Mild Psoriasis - Pipeline by Avexxin AS, H1 2015 14
Mild Psoriasis - Pipeline by Convoy Therapeutics, Inc., H1 2015 15
Mild Psoriasis - Pipeline by Delenex Therapeutics AG, H1 2015 16
Mild Psoriasis - Pipeline by GlycoMar Limited, H1 2015 17
Mild Psoriasis - Pipeline by OPKO Health, Inc., H1 2015 18
Mild Psoriasis - Pipeline by Soligenix, Inc., H1 2015 19
Mild Psoriasis - Pipeline by UCB S.A., H1 2015 20
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Stage and Target, H1 2015 23
Number of Products by Stage and Mechanism of Action, H1 2015 25
Number of Products by Stage and Route of Administration, H1 2015 27
Number of Products by Stage and Molecule Type, H1 2015 29
Mild Psoriasis Therapeutics - Recent Pipeline Updates, H1 2015 43
Mild Psoriasis - Dormant Projects, H1 2015 45
Mild Psoriasis - Discontinued Products, H1 2015 46

List of Figures
Number of Products under Development for Mild Psoriasis, H1 2015 7
Number of Products under Development for Mild Psoriasis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Comparative Analysis by Early Stage Products, H1 2015 11
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Top 10 Targets, H1 2015 22
Number of Products by Stage and Top 10 Targets, H1 2015 22
Number of Products by Top 10 Mechanism of Actions, H1 2015 24
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 24
Number of Products by Top 10 Routes of Administration, H1 2015 26
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 27
Number of Products by Top 10 Molecule Types, H1 2015 28
Number of Products by Stage and Top 10 Molecule Types, H1 2015 29

Explore more reports on Dermatology therapeutics at
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/dermatology-therapeutics